Synthaverse R&D and Onko BCG

KARMAR, Bouygues Bâtiment International’s Polish subsidiary, delivered two strategic life & science buildings - the Research & Development Center and the ONKO BCG Plant - in Lublin, Poland. These projects are part of the SYNTHAVERSE Biotechnology Innovation Center (Onko BCG Branch), where technologies related to vaccinology for tuberculosis prevention (BCG) and immunology for cancer treatment are being perfected.

Commissioned by SYNTHAVERSE S.A., the project strengthens Europe’s capabilities in the prevention of tuberculosis and immune-based cancer therapies.

With a total area of 2,764 m², the R&D Center is purpose-built for the development of drug substances, clinical manufacturing, and commercial launches. Ancillary spaces include modern offices, as well as social and technical facilities. The building integrates advanced installations, including complex mechanical ventilation and air conditioning, water generators, nitrogen, and technological steam systems - all essential for biopharma innovation.

The second building, the ONKO BCG Drug Production Plant, has a total area of 3,250 m². It includes cleanrooms of the highest cleanliness classes, which require specialized equipment and a strict performance regime during both the design and construction stages. The facility's high standards are confirmed by positive DQ, IQ, and OQ validation and qualification reports.

The facilities completed for Synthaverse produce key Onko BCG products and tuberculosis vaccines, which form the foundation of modern vaccinology and cancer immunotherapy.